Cimalgex (3 - 4 kg)

4 x 8 pc

Chewable tablet

Active substance

Cimicoxib : 8 mg

ATC code

QM01AH93 Cimicoxib

QM01AH Coxibs

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Dogs

Indications

For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri- operative pain due to orthopaedic or soft tissue surgery, in dogs.

Dose to be administered and administration route

Oral use.

The recommended dose of cimicoxib is 2 mg/kg bodyweight, once daily. The following table is presented as an example of how the tablets and tablet parts could be used in order to reach the recommended dose.

Bodyweight kg	8 mg	30 mg	80 mg
2	1/2
3	1
4	1
5		1/3
6	1+1/2
7‐8	2
9‐11	2+1/2
12	3
13‐17		1
18‐22			1/2
23‐28		1+2/3
29‐33		2
34‐38		2+1/3
39‐44			1
45‐48		3
49‐54			1+1/4
55‐68			1+1/2

The choice of the most suitable tablet type or tablet parts is left to the discretion of the veterinarian based on the circumstances in each case, without leading to important over- or underdosing.

Treatment duration:

• Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian.

• Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.

The veterinary medicinal product can be administered with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.

Adverse reactions

Very common

(>1 animal / 10 animals treated):

Vomiting¹, Diarrhoea¹

Rare

(1 to 10 animals /

10,000 animals treated):

Digestive tract haemorrhage², Gastric ulceration², Anorexia, Lethargy, Polyuria, Polydipsia

Very rare

(<1 animal / 10,000 animals treated,

including isolated reports):

Elevated renal parameters, Renal failure³

¹ Mild and transient gastro-intestinal disorders

² Serious gastro-intestinal disorders

³Kidney function should be monitored during long-term NSAID treatment. If any observed adverse effect persists after stopping treatment, the advice of a veterinarian should be sought.

If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy or worsening of renal or hepatic biochemistry parameters occur, use of the product should be discontinued and appropriate monitoring and/or treatment should be put in place. As with other NSAIDs, serious adverse effects can occur and, in rare cases, may be fatal

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.